Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma
Brief Summary: This phase I/II trial studies the side effects and best dose of chimeric antigen receptor (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells when given together with high-dose chemotherapy and stem cell transplant and to see how well they work in treating participants with B-cell lymphoma. Cord blood-derived CAR-NK cells may react against the B-cell lymphoma cells in the body, which may help to control the disease. Giving chemotherapy before a stem cell transplant may help kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.


Options:
A: Arm Label: Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Safety Management Study): Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab | Arm Label: Phase 2 (Safety Management Study): Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab | Arm Label: Phase 2 (Safety Management Study): Cohort 5; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Rituximab, Drug: Doxorubicin, Drug: Prednisone, Drug: Vincristine, Drug: Ifosfamide, Drug: Carboplatin, Drug: Etoposide, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Cisplatin | Arm Label: Phase 2 (Safety Management Study): Cohort 6; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab, Drug: Methylprednisolone | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: High-dose methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Ifosfamide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 6
B: Arm Label: Mixed CD19/CD20 CAR-T Transfer; Type: EXPERIMENTAL; Interventions: Biological: Mixed CD19/CD20 CAR-T Transfer | Intervention Type: BIOLOGICAL; Name: Mixed CD19/CD20 CAR-T Transfer; Assigned to Arm(s): Mixed CD19/CD20 CAR-T Transfer
C: Arm Label: Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT); Type: EXPERIMENTAL; Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation, Drug: Carmustine, Drug: Cytarabine, Drug: Etoposide, Biological: Filgrastim, Drug: Melphalan, Biological: Rituximab, Biological: Umbilical Cord Blood-derived Natural Killer Cells | Intervention Type: PROCEDURE; Name: Autologous Hematopoietic Stem Cell Transplantation; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Umbilical Cord Blood-derived Natural Killer Cells; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)
D: Arm Label: ACTR707 in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR707, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR707; Assigned to Arm(s): ACTR707 in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR707 in combination with rituximab

Answer: C